8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 13, 2026·SEC
Embecta Corp.(EMBC)Earnings, Financials & Key Ratios
EMBC•NASDAQ
$3.11
1.9× P/E·Price updated Jun 25, 2026
AboutEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.Show more
- Revenue$1.08B-3.8%
- EBITDA$380M+75.5%
- Net Income$95M+21.8%
- EPS (Diluted)1.62+20.9%
- Gross Margin62.89%-3.1%
- EBITDA Margin35.21%+82.5%
- Operating Margin30.48%+96.5%
- Net Margin8.83%+26.7%
EMBC Price & Volume
Embecta Corp. (EMBC) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Challenges Embecta Financial Stability
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Contracting
Profitability:Strained
Financial Position:Vulnerable
Cash Flow:Mixed
Primary Risk:Negative equity and leverage
"Embecta faces significant structural headwinds as its core insulin delivery business experiences a 14.4% year-over-year revenue decline, raising concerns regarding the sustainability of its current operating model. The company's negative equity position of -$626.1M and high debt load of $1.4B create a precarious financial profile that limits strategic flexibility. Investors should monitor whether the firm can stabilize its volatile gross margins, which dropped from 69.0% in 2024Q3 to 51.4% in 2026Q2, before committing capital to this turnaround effort."
Verdict Logic
the company's inability to maintain positive net income, which fell to -$4.1M in 2026Q2, combined with a deteriorating equity base, suggests significant execution risk that outweighs the current 17.0% dividend yield.
EMBC Growth Metrics
Embecta Corp. (EMBC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-0.09%
3 Years-1.47%
TTM-3.43%
Profit CAGR
10 Years-
5 Years-25.92%
3 Years-24.72%
TTM114.78%
EPS CAGR
10 Years-
5 Years-26.4%
3 Years-25.32%
TTM37.37%
Return on Capital
10 Years54.33%
5 Years43.87%
3 Years28.46%
Last Year37.84%
EMBC Recent Earnings
Embecta Corp. (EMBC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.27-35.7%
$0.42
Rev
$222M-5.9%
$236M
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$0.71+6.0%
$0.67
Rev
$261M+1.2%
$258M
Q4 2025
Nov 25, 2025Metric
Actual
Est
EPS
$0.50-28.6%
$0.70
Rev
$264M+2.2%
$258M
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$1.12+146.2%
$0.46
Rev
$296M+11.2%
$266M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.27vs $0.42-35.7% | $222Mvs $236M-5.9% |
| Q1 2026 | Feb 5, 2026 | $0.71vs $0.67+6.0% | $261Mvs $258M+1.2% |
| Q4 2025 | Nov 25, 2025 | $0.50vs $0.70-28.6% | $264Mvs $258M+2.2% |
| Q3 2025 | Aug 8, 2025 | $1.12vs $0.46+146.2% | $296Mvs $266M+11.2% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Embecta Corp. (EMBC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.11 | $184.51M | 1.92 | -3.8% | 8.83% | — | 19.1% | |
| $66.87 | $212.92M | 19.22 | -5.83% | 28.9% | 9.13% | — | |
| $477.22 | $12.07B | -164.56 | 8.92% | -1.61% | -1.57% | — | |
| $15.05 | $1.71B | -12.34 | 8.28% | -25.66% | -50.82% | — | |
| $93.12 | $3.2B | 32.22 | 7.57% | 7.67% | 8.23% | — | |
| $70.83 | $4.22B | 33.25 | 11.66% | 9.03% | 8.95% | — |
Compare EMBC vs Peers
Embecta Corp. (EMBC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EMBC SEC Filings & Documents
Embecta Corp. (EMBC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when EMBC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EMBC Frequently Asked Questions
Embecta Corp. (EMBC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Embecta Corp.'s revenue?
Embecta Corp. (EMBC) reported $1.04B in revenue for fiscal year 2025. This represents a 6% decrease from $1.11B in 2019.
How fast is Embecta Corp. growing?
Embecta Corp. (EMBC) saw revenue decline by 3.8% over the past year.
Is EMBC profitable?
Yes, Embecta Corp. (EMBC) is profitable, generating $111.9M in net income for fiscal year 2025 (8.8% net margin).
Dividend & Returns
Does EMBC pay dividends?
Yes, Embecta Corp. (EMBC) pays a dividend with a yield of 19.10%. This makes it attractive for income-focused investors.
What is Embecta Corp.'s free cash flow?
Embecta Corp. (EMBC) generated $174.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.